Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial
Authors:
- J.I WeitzJWJ.I Weitz
- C.D JoynerCJC.D Joyner
- A.L MorrisAMA.L Morris
- P ThérouxPTP Théroux
Open Access
- 1 September 2000
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 21 (17) , 1473-1481
Abstract
Aims To compare effects of heparin and hirudin on biochemical markers of coagulation. Methods and Results Patients (n=395) with unstable angina or myocardial infarction without ST elevation were randomized to a 72-h infusion of one of three regimens: unfractionated heparin (bolus of 5000IU followed by an infusion of 1200IU.h−1), low-dose hirudin (HBW 023; 0·2mg.kg−1bolus followed by 0·10mg.kg−1.h−1) or medium-dose hirudin (0·4mg.kg−1bolus followed by 0·15mg.kg−1.h−1). Infusions were adjusted to maintain an activated partial thromboplastin time of between 60–100s. Activated partial thromboplastin time, prothrombin fragment 1.2 (F1.2), thrombin antithrombin III complex and D-dimer were measured before, during and after the infusion. Median activated partial thromboplastin time was similar in the two groups early on, but was significantly lower in the heparin group than in the combined hirudin group 48h after starting the infusion (53s and 75s, respectively;PP−1and 2·3μg.l−1, respectively, at 6h (P−1and 2·3μg.l−1, respectively, at 48h (P−1and 260ng.ml−148h after starting the infusion in the heparin and hirudin groups, respectively (P−1and 280ng.ml−1, respectively (PConclusions The greater reduction of thrombin antithrombin III and D-dimer during the hirudin infusion supports the hypothesis that hirudin is a more potent antithrombin agent than heparin. Increased D-dimer levels after stopping heparin or hirudin suggest that there is an ongoing pro-coagulant state. These results point to the greater efficacy of hirudin in preventing early clinical events (death, myocardial infarction and refractory ischaemia) compared with heparin that have been observed in large randomized trials. Persistent activation of coagulation afterstopping infusions in our study suggests that a longer course of antithrombotic treatment may be needed to pacify the thrombus.Keywords
This publication has 24 references indexed in Scilit:
- The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease1999
- MONITORING OF RECOMBINANT HIRUDIN: ASSESSMENT OF A PLASMA-BASED ECARIN CLOTTING TIME ASSAYThrombosis Research, 1997
- Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasmaThrombosis Research, 1995
- The heparin rebound phenomenon?Does it offer insights toward understanding the pathobiology of coronary thrombosis and its treatment?Journal of Thrombosis and Thrombolysis, 1995
- Reactivation of Unstable Angina after the Discontinuation of HeparinNew England Journal of Medicine, 1992
- Hirudin and Derivatives as Anticoagulant AgentsThrombosis and Haemostasis, 1991
- Determination of Human Prothrombin Activation Fragment 1+2 in Plasma with an Antibody against a Synthetic PeptideThrombosis and Haemostasis, 1991
- Regulation of Thrombin Generation and FunctionsSeminars in Thrombosis and Hemostasis, 1988
- Determination of Human Thrombin-Antithrombin III Complex in Plasma with an Enzyme-Linked Immunosorbent AssayThrombosis and Haemostasis, 1988
- An immunoassay for human D dimer using monoclonal antibodiesThrombosis Research, 1983